BioAesthetics Surpasses Series A Goal Further Advancing the Nipple-Areolar Complex Graft to Clinical Use

BioAesthetics Corporation today announced that it has significantly surpassed its Series A funding goal of $2.5 million, further advancing its inaugural product — the nipple-areolar complex (NAC) graft, or NACgraftTM, for patients who are undergoing breast reconstruction following breast cancer and mastectomy — to clinical use.